ANSWER: D

Rationale:

The clinical presentation — fever, rash, lymphadenopathy, hepatitis, eosinophilia, and multi-organ involvement developing three to eight weeks after starting a drug — is the defining syndrome of DRESS (Drug Reaction with Eosinophilia and Systemic Symptoms), also known as drug-induced hypersensitivity syndrome (DiHS). DRESS is classified as a Type B (Bizarre) adverse drug reaction in the Rawlins and Thompson system: it is idiosyncratic, dose-independent, unpredictable from the drug's primary pharmacological mechanism, and relatively rare (estimated 1 in 1,000 to 1 in 10,000 exposures for implicated drugs). The immunological mechanism involves Type IV (T cell-mediated) hypersensitivity, specifically implicating CD4+ and CD8+ T cell responses to drug-modified proteins, frequently compounded by reactivation of latent herpesviruses (HHV-6, HHV-7, EBV, CMV) — a unique feature that distinguishes DRESS from other severe cutaneous adverse reactions. Strong HLA associations have been identified for specific drug-DRESS pairs: HLA-A*3101 and carbamazepine-DRESS in European and Japanese populations, HLA-B*5801 and allopurinol-DRESS in Han Chinese. Aromatic anticonvulsants (carbamazepine, phenytoin, phenobarbital, lamotrigine) are among the highest-risk implicated drugs. DRESS carries a mortality of approximately 10% from hepatic failure, myocarditis, or interstitial nephritis. Option A is incorrect — dose-dependent hepatotoxicity is a Type A reaction; DRESS is distinctly dose-independent and immune-mediated. Option B is incorrect — Type D reactions refer to carcinogenesis, teratogenesis, and mutagenesis; DRESS is not a neoplastic process. Option C is incorrect — Type C reactions refer to cumulative dose-dependent organ toxicity; DRESS is idiosyncratic. Option E is incorrect — Type F reactions refer to unexpected therapeutic failure, not drug hypersensitivity syndromes.

ANSWER: E

Rationale:

This question requires distinguishing pharmacokinetic from pharmacodynamic drug interactions — a conceptual distinction with major clinical implications. Aprepitant (as a moderate CYP3A4 inhibitor during its initial dosing phase) reduces the hepatic and intestinal metabolism of docetaxel, a CYP3A4 substrate. The result is a pharmacokinetic interaction: docetaxel clearance is reduced, its AUC increases, and systemic drug concentrations are higher than intended for the prescribed dose. Docetaxel's myelotoxicity is concentration- and AUC-dependent — higher AUC produces greater and more prolonged bone marrow suppression, increasing the risk and severity of febrile neutropenia. This is a pharmacokinetic interaction because it operates at the level of drug plasma concentration (metabolic pathway), not at the level of molecular targets or biological effectors. A pharmacodynamic interaction, by contrast, would occur if two drugs each independently suppressed neutrophil production through their own mechanisms — for example, concurrent use of two myelosuppressive chemotherapy agents, or combined methotrexate and trimethoprim-sulfamethoxazole. The critical distinction: pharmacokinetic interactions change how much drug reaches the target; pharmacodynamic interactions change what happens at the target given the same drug concentration. Option A is incorrect — aprepitant is a CYP3A4 inhibitor, not inducer; it would increase, not decrease, docetaxel exposure. Option B is incorrect — docetaxel is administered intravenously; gastric pH has no effect on its bioavailability. Option C is incorrect — the aprepitant-CYP3A4 interaction meaningfully augments docetaxel myelotoxicity and is clinically relevant. Option D incorrectly classifies a transporter-mediated change in intracellular drug concentration as pharmacodynamic; transporter effects are pharmacokinetic (distribution) interactions.

ANSWER: D

Rationale:

This case illustrates the clinical "multiple hit" model of TdP risk — drug-induced QT prolongation rarely emerges from a single factor but from the convergence of additive and synergistic contributors. Each element independently contributes, and their combination creates risk greater than the sum of individual contributions. Hydroxychloroquine is a well-documented hERG channel blocker requiring baseline and periodic ECG monitoring. Azithromycin has well-characterized hERG-blocking properties; population-based studies showing increased cardiovascular mortality prompted major regulatory attention. Ondansetron is a 5-HT3 antagonist with hERG-blocking activity — regulatory agencies have issued dose-restriction warnings, particularly for intravenous doses ≥32 mg. Hypokalemia (K 3.1 mEq/L) reduces the electrochemical driving force for potassium efflux through hERG channels and paradoxically increases hERG channel sensitivity to drug blockade — a counterintuitive electrophysiological property. A QTc of 512 ms represents severe prolongation warranting active management. Immediate steps: continuous ECG monitoring, discontinue azithromycin and ondansetron, aggressively replete potassium (target >4.0 mEq/L) and magnesium (target >0.8 mmol/L — first-line treatment for TdP if it occurs). Option A is incorrect — all three medications independently prolong QTc through hERG blockade; dismissing them is clinically dangerous. Option B is incorrect — the other two medications are major contributing factors. Option C is incorrect — ondansetron prolongs QT primarily through direct hERG blockade, not through a pharmacokinetic CYP interaction. Option E is incorrect — a QTc of 512 ms carries substantial TdP risk; all modifiable factors must be addressed urgently.

ANSWER: C

Rationale:

The rifampicin-warfarin interaction is the most clinically dramatic example of CYP enzyme induction producing therapeutic failure. Rifampicin activates pregnane X receptor (PXR) and constitutive androstane receptor (CAR), transcriptionally upregulating CYP3A4, CYP2C9, CYP2C19, CYP2B6, CYP1A2, and P-glycoprotein. For warfarin, CYP2C9 induction is the primary mechanism: increased CYP2C9 enzyme protein accelerates S-warfarin hydroxylation to its inactive metabolite, reducing S-warfarin plasma concentration and anticoagulant activity. The INR falls from therapeutic to sub-therapeutic, leaving a patient with a prosthetic mechanical valve at acute thromboembolism risk — one of the highest-stakes consequences of any drug interaction. Prescribing response: (1) anticipate the need for warfarin dose escalation of 2–5 fold; (2) monitor INR every 3–5 days during dose titration; (3) recognize that induction builds over 1–2 weeks after rifampicin initiation and resolves over 2–4 weeks after discontinuation; (4) plan a warfarin dose reduction schedule when rifampicin is stopped to prevent bleeding toxicity as induction reverses. Option A is incorrect — rifampicin is an inducer, not a displacer; the interaction is metabolic, not distributional. Option B is incorrect — rifampicin does not inhibit VKORC1; the interaction is pharmacokinetic (metabolic induction), not pharmacodynamic antagonism. Option D is incorrect — while rifampicin induces intestinal P-gp, the dominant warfarin interaction mechanism is CYP2C9 induction; warfarin has near-complete oral bioavailability (~100%), making P-gp-mediated absorption effects minor contributors. Option E is incorrect — rifampicin does not reduce hepatic blood flow in a manner that reduces first-pass metabolism; the falling INR is pharmacokinetically real, not an assay artifact.

ANSWER: E

Rationale:

The ritonavir pharmacokinetic boosting strategy transforms what would be an adverse drug interaction in other contexts into a designed therapeutic strategy. Ritonavir at full antiretroviral doses (600 mg twice daily) is poorly tolerated; at low booster doses (100–200 mg once or twice daily), it provides potent mechanism-based CYP3A4 inhibition with minimal antiviral contribution. By inhibiting CYP3A4-mediated metabolism of darunavir and other HIV protease inhibitors (lopinavir, atazanavir, saquinavir), ritonavir markedly increases protease inhibitor AUC and Cmin — allowing lower doses, reduced dosing frequency, improved virological suppression, and reduced pill burden. Cobicistat (COBI) was subsequently developed as a pure pharmacokinetic booster — selective CYP3A4 inhibition with no antiretroviral activity — incorporated into fixed-dose combinations (Stribild, Genvoya) to boost elvitegravir, darunavir, and atazanavir. The deliberate enzyme inhibition strategy extends well beyond HIV: carbidopa inhibits peripheral aromatic L-amino acid decarboxylase, preventing peripheral levodopa conversion to dopamine and increasing CNS levodopa delivery — a metabolic enzyme inhibition strategy that reduces levodopa dose requirements by approximately 75%; cilastatin inhibits renal dehydropeptidase-I that would otherwise inactivate imipenem in the proximal tubular lumen, preserving imipenem urinary concentrations for urinary tract infection treatment. Option A is incorrect — ritonavir inhibits, not induces, CYP3A4; CYP induction would reduce, not boost, darunavir concentrations. Option B is incorrect — deliberate pharmacokinetic interactions extend well beyond HIV pharmacology. Option C is incorrect — ritonavir's boosting mechanism is CYP3A4 inhibition, not HIV protease active site competition. Option D is incorrect — ritonavir's primary boosting mechanism is CYP3A4 inhibition, not P-gp induction; grapefruit juice is never a deliberate clinical strategy.